Respiratory Syncytial Virus: Current Progress in Vaccine Development
Respiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the findi...
Main Authors: | Julia L. Hurwitz, Sherri L. Surman, Rajeev Rudraraju, Robert Sealy, Bart G. Jones |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-02-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/5/2/577 |
Similar Items
-
Need for a safe vaccine against respiratory syncytial virus infection
by: Joo-Young Kim, et al.
Published: (2012-09-01) -
Novel intranasal proteosome-based respiratory syncytial virus (RSV) vaccines elicit protection in mice without the risk of enhanced pathology or eosinophila by triggering innate immune pathways
by: Cyr, Sonya L.
Published: (2007) -
Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population
by: Laura M. Stephens, et al.
Published: (2021-06-01) -
Neonatal Calf Infection with Respiratory Syncytial Virus: Drawing Parallels to the Disease in Human Infants
by: Timothy A. Reinhardt, et al.
Published: (2012-12-01) -
Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia—Implications for Vaccine Design
by: Emma Rey-Jurado, et al.
Published: (2017-03-01)